For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is associated with lower bleeding risk, without an increase in ischemic events, according to a review published online Feb. 18 in the Annals of Internal Medicine.